Back to top
more

ResMed (RMD)

(Delayed Data from NYSE)

$273.29 USD

273.29
552,903

+1.58 (0.58%)

Updated Sep 18, 2025 04:00 PM ET

After-Market: $273.28 -0.01 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (98 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

LabCorp (LH) to Report Q2 Earnings: What's in the Cards? (revised)

by Zacks Equity Research

LabCorp's (LH) second-quarter base-business performance is expected to have registered a faster recovery rate compared to the first quarter.

Zacks Equity Research

Thermo Fisher (TMO) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

With vaccine rollouts through Q2, Thermo Fisher's (TMO) Life-Science Solutions segment is likely to have registered top-line contributions from vaccine and therapy production supplies.

Trina Mukherjee headshot

Grab these 3 MedTech Stocks That Outperformed S&P 500 YTD

by Trina Mukherjee

Snap up these three top stocks, WST, PAHC and RMD, which continue to show promise amid the pandemic and can turn out to be prudent investment choices.

Zacks Equity Research

Zacks.com featured highlights include: Gartner, Landstar System, ResMed and DaVita

by Zacks Equity Research

Zacks.com featured highlights include: Gartner, Landstar System, ResMed and DaVita

Zacks Equity Research

4 GARP Stocks to Scoop Up for Maximum Returns

by Zacks Equity Research

If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.

Trina Mukherjee headshot

Digital Health Momentum is Here to Stay: 3 MedTech Stocks in Focus

by Trina Mukherjee

Here we look at three stocks, MDRX, CERN and RMD, that investors can keep a watch on the back of their robust digital health prospects.

Zacks Equity Research

ResMed (RMD) Hits a New 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about ResMed (RMD) on solid digital health growth potential along with rising demand for masks and other accessories.

Zacks Equity Research

ResMed (RMD) Moves 6% Higher: Will This Strength Last?

by Zacks Equity Research

ResMed (RMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

ResMed (RMD) Rallies as Philips Falters on Mass Product Recall

by Zacks Equity Research

The full U.S. launch of ResMed (RMD) AirSense 11 is expected any time in 2021, which might receive bigger market acceptance capitalizing on its current peer position.

Zacks Equity Research

Here's Why You Should Hold on to ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about ResMed (RMD), owing to its potential in digital health and consistent high demand for its masks.

Zacks Equity Research

ResMed (RMD) Q3 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

Lower device sales including weak demand for ventilators due to COVID-19 hurt ResMed's (RMD) Q3 top line.

Zacks Equity Research

ResMed (RMD) Q3 Earnings Top Estimates

by Zacks Equity Research

ResMed (RMD) delivered earnings and revenue surprises of 6.56% and -2.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Trina Mukherjee headshot

Medical Products' Apr 29 Earnings Roster: TMO, BAX & More

by Trina Mukherjee

The Medical Product companies' first-quarter results are likely to reflect robust earnings and revenue growth on solid base business recovery.

Zacks Equity Research

Earnings Preview: ResMed (RMD) Q3 Earnings Expected to Decline

by Zacks Equity Research

ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Debanjana Dey headshot

4 Critical Care Device Stocks to Deflect the COVID-19 Curveball

by Debanjana Dey

Cantel (CMD), Hill-Rom (HRC), LeMaitre (LMAT) and Masimo (MASI) can prove to be prudent investment choices in the critical care industry of the MedTech sector.

Debanjana Dey headshot

3 Beaten-Down MedTech Stocks to Scoop Up Amid the Pandemic

by Debanjana Dey

Here are some dirt-cheap MedTech value stocks - IVC, MCK, HRC - which are expected to provide long-term gains in 2021.

Zacks Equity Research

Here's Why You Should Hold on to ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about ResMed (RMD), owing to its potential in digital health and consistent high demand for its critical care products.

Urmimala Biswas headshot

Fed Eyes Faster Recovery in 2021: 3 MedTech Stocks to Buy

by Urmimala Biswas

MedTech stocks like INMD, BASI and SMLR are expected to maintain market-beating momentum in 2021.

Zacks Equity Research

Why Is ResMed (RMD) Down 10.7% Since Last Earnings Report?

by Zacks Equity Research

ResMed (RMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

PAHC or RMD: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PAHC vs. RMD: Which Stock Is the Better Value Option?

Urmimala Biswas headshot

3 MedTech Stocks Likely to Top Estimates This Earnings Season

by Urmimala Biswas

Strong signs of rebound in base sales volumes make us optimistic about VIVO, XRAY, and PDCO's results.

Zacks Equity Research

ResMed (RMD) Q2 Earnings Surpass Estimates, Margins Rise

by Zacks Equity Research

ResMed (RMD) reported second-quarter fiscal 2021 revenues of $800 million, up 9% from a year ago.

Zacks Equity Research

ResMed (RMD) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

ResMed (RMD) delivered earnings and revenue surprises of 15.57% and 3.60%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

The Zacks Analyst Blog Highlights: ResMed, Invacare, Fresenius, Henry Schein and Quest Diagnostics

by Zacks Equity Research

The Zacks Analyst Blog Highlights: ResMed, Invacare, Fresenius, Henry Schein and Quest Diagnostics

Debanjana Dey headshot

4 MedTech Underperformers Poised for a Turnaround in 2021

by Debanjana Dey

Here are some dirt-cheap MedTech value stocks which are expected to provide long-term gains in 2021.